Patients with hormone-positive breast cancer are usually treated with anti-hormone therapies such as tamoxifen or aromatase inhibitors. However, many of these patients are resistant to these drugs or develop resistance during treatment, allowing their breast cancer to return.

The Endocrinology team aims to understand how and why some patients’ cancers are resistant and others aren't.

Professor Holen’s team is studying the role of two proteins in breast cancer spread to bone.

 

Patients with triple negative breast cancer have limited treatment options because their breast tumours lack the receptors which targeted therapies like tamoxifen and Herceptin act against.

Mutations in F-box genes could lead to new treatments for breast cancer patients.

Dr Huang hopes that identifying new weak spots in cancer cells will lead to new treatments.